Lentitek is developing solutions to help amazing therapies get to more people. Gene therapies, and gene-modified cell therapies such as CAR-T are proving themselves as incredible life changing and life saving therapies. However they face an issue with the production yield of the viral vector. Lentitek is developing solutions to improve the viral yield by 10 fold and beyond. This will help these developers reduce production costs and allow these amazing therapies get into more people who really need it!
External link for Lentitek
Edinburgh, GB
Missed our talk at Advanced Therapies USA in Philly? Come to our booth S6 in Startup Zone!
Standing room only for our latest Lentitek data at #advancedtherapies in Philadelphia. Thanks to everyone that attended. If you missed our talk, or want to hear more, come to our booth in the Startup Zone. You cannot miss us - we are in GFP green hoodies! #lentivirus #CART #startup
Attending Advanced Therapies USA in Philadelphia? Come and chat to us! Our founders Leif Anderson and Adam Inche will be attending the Terrapinn Advanced Therapies Conference USA in Philadelphia on the 12th and 13th of November. If you have concerns about CAR contamination of your lentivirus; vector genome splicing and integrity; or payload toxicity during production - come and see us at Stand S6 in the Startup Zone. Alternatively, Adam Inche will be giving a presentation describing the advantages of using the Lentitek solution: Tuesday 12th (Day 1) at 10:45am in the Seminar Theatre. Hope to see you in Philly! #advancedtherapies #lentivirus #CARtherapies
A very warm welcome to Emily Powell, PhD - the newest member of the Lentitek team! Emily is a very accomplished lentivirus scientist and we are super excited that she will be joining us as our Viral Vector Manufacturing Lead. #growth #newstart #lentivirus
Another exciting announcement as we take the first steps in getting critical customer feedback on our technology through our partnership with a leading vector CDMO. We are thrilled to be collaborating with Rentschler Biopharma and their amazing team of scientists as they evaluate the Lentitek technology with their novel LVV manufacturing toolbox. #LVV #collaboration #lentivirus
We are excited to announce our collaboration with Lentitek, to evaluate their cutting-edge promoter technology for producing lentiviral vectors (LVVs) using our novel LVV manufacturing toolbox. Lentitek’s technology aims to enhance lentiviral vector quality, purity and yield by minimizing vector genome splicing and payload breakthrough expression, ensuring safer and more effective CAR-T therapies. LVVs are crucial starting materials for the production of gene-modified CAR-T and other gene therapies. CAR-T therapies have shown remarkable potential in treating certain types of cancer, however, their production and purification remains challenging. At Rentschler Biopharma, we are committed to delivering innovative, safe and high-quality advanced therapies for our clients and their patients. By partnering with Lentitek, we aim to push the boundaries of LVV production, address manufacturing challenges related to cell and gene therapies, and evaluate this novel technology as a potential new offering to our clients. Stay tuned for updates on this exciting collaboration with Lentitek! #RentschlerBiopharma #AdvancedTherapies #LVV
Lentitek reposted this
We are excited to announce our collaboration with Lentitek, to evaluate their cutting-edge promoter technology for producing lentiviral vectors (LVVs) using our novel LVV manufacturing toolbox. Lentitek’s technology aims to enhance lentiviral vector quality, purity and yield by minimizing vector genome splicing and payload breakthrough expression, ensuring safer and more effective CAR-T therapies. LVVs are crucial starting materials for the production of gene-modified CAR-T and other gene therapies. CAR-T therapies have shown remarkable potential in treating certain types of cancer, however, their production and purification remains challenging. At Rentschler Biopharma, we are committed to delivering innovative, safe and high-quality advanced therapies for our clients and their patients. By partnering with Lentitek, we aim to push the boundaries of LVV production, address manufacturing challenges related to cell and gene therapies, and evaluate this novel technology as a potential new offering to our clients. Stay tuned for updates on this exciting collaboration with Lentitek! #RentschlerBiopharma #AdvancedTherapies #LVV
A very warm welcome to Michael Roberts who has just joined our board! Today we announce that Lentitek has appointed Michael Roberts as a non-executive director. The appointment of Dr Roberts significantly strengthens the Lentitek team both commercially and scientifically. Adam Inche, Chief Executive Officer of Lentitek commented: “It is with enormous pleasure that we welcome Dr Roberts to the Lentitek team. Michael brings a phenomenal depth of knowledge and experience both scientifically and commercially which will prove invaluable as we scale the business” As a prominent scientist in the field of gene regulation, Dr Michael Roberts founded Synpromics Ltd in 2010, which pioneered the industrialisation of synthetic promoter design. After achieving significant commercial success in the cell and gene therapy space, Synpromics was acquired by Asklepios BioPharmaceutical, Inc. (AskBio) in 2019. On his appointment as Director at Lentitek Dr Roberts commented “I have been keenly interested in Lentitek and was delighted to be asked to join the team. Their technology provides an elegant solution to some of the most pressing concerns in lentivirus manufacturing.” Dr Roberts currently serves as CEO for Chromatin Bioscience, a leading provider of synthetic promoter design services for the cell and gene therapy sector with a prestigious list clients. #lentivirus #atmps
Thanks to all of those involved in getting this super competitive award. Really fantastic work! #collaboration #lenti #CART
£11.3 million grant funding, shared across 16 amazing companies - and Lentitek is one of them! Innovate UK announced the awarding of its #CancerTheraputics program and we are delighted to share with you that Lentitek is one of the 16 companies selected for Industry Led R&D. Our joint application with John Counsell of UCL will look at how the next generation of in vivo CAR-T therapies can be enabled using the Lentitek technology. Contamination of the #lentivirus with the CAR protein is known, but has not entered into mainstream discussion. We are looking to demonstrate how the current vector production methods are impacted in mixed cell environments, and how reduction of the CAR payload decorating the lentivirus envelope is a key part to enabling #invivoCART. If you would like to be a part of our journey, we are #hiring to support this project. For more details of the other great companies helping transform cancer therapies see here: https://lnkd.in/eKGZVF5M
We're #hiring a new Manufacturing Lead in London Area, United Kingdom. Apply today or share this post with your network.
Please join our CEO Adam Inche on Sept 5th as he presents some of the latest exciting results from Lentitek. Adam will outline how lentivirus used in #CARtherapies can be contaminated with the CAR itself. He will explore the potential impacts this has and why this would be of concern to the regulators. Thanks to our friends at Unchained Labs for supporting our pivotal lentivirus characterisation work.
Unlock the key to safer, more effective cell therapies! Join our exclusive webinar to explore advanced strategies for improving lentiviral (LV) vector quality in cell therapy manufacturing. Register now: https://lnkd.in/g9VjtCCx Presented by: Dr. Alex Shephard and Dr. Adam Inche Unchained Labs #CellTherapy #LentiviralVectors #GeneTherapy #Biomanufacturing #CAR_Therapy #VectorQuality #Webinar
We are very pleased to announce that we have launched a new Lentitek website! This contains a lot more information on the science and applications for the Lentitek technology as well as the benefits the system can bring to lentivirus developers. Please visit our new site at www.lentitek.com #ATMP #lentivirus